Welcome to Metabiomics.com

Metabiomics is developing a non-invasive stool test for the early detection of colon polyps and colorectal cancer based an advanced interrogation of the human gut microbiome.

Preventing Cancer

We are focused on developing a non-invasive microbiome test for the earlier and more accurate detection of colon polyps and colorectal cancer

Healthy Microbiome

Metabiomics is developing a pipeline of services for characterizing gut microbiome health and disease

MultiTag™ Sequencing

Our patented MultiTag™ DNA sequencing technology enables breakthrough next-generation sequencing and microbiome assays

About Us

Metabiomics is an early stage molecular diagnostics company that is developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences.

Investor Resources and News

Metabiomics has developed strategies for rapid commercialization and growth built on a strong technology foundation and a management team with extensive and diverse experience. Please contact us directly for more information on available investment opportunities.

Company News

Microbiome R&D and Business Collaboration Forum

San Diego, CA September 10, 2015    Metabiomics is pleased to be attending the 3rd annual Global Engage Microbiome R&D and Business Collaboraton Forum.  Greg Kuehn, President and COO will be giving a talk on Day 2 (sept 11) covering the company's platform, vision and...

Clinical Research News and Resources

Metabiomics conducts microbiome systems biology, molecular diagnostics, and gastroenterology clinical research in collaboration with leading medical institutions and strategic partners across the North America, Europe and Asia.  Please contact us directly to explore strategic alliance, collaboration, and technology licensing opportunities.

Research News

MultiTag™ Sequencing Patent Award in US Clears Path for Metabiomics Colorectal Cancer and Gastrointestinal Disease Molecular Diagnostic Clinical Trials

The award today of US Patent 8,603,749, MutiTag Sequencing for Ecogenomics Analysis, represents a major milestone for Metabiomics by providing exclusive rights to fundamental next-generation DNA sequencing analysis technology for multiplexed ‘barcoded” sequencing of multiple samples in high-throughput analyses in the field of gastrointestinal diagnostics and therapeutic biomarker discovery.

Metabiomics Safe Harbor Statement: This press website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential results and future outcomes our clinical research and business plan; ability to discover biomarkers and diagnostic tests; our beliefs regarding the need for and value of molecular diagnostics; and the focus and attributes of the company’s product pipeline, including the ability of the company’s tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the applicability of initial next generation sequencing studies to future results; the risk that we may not obtain or maintain reimbursement for diagnostic tests we may develop, both domestically and abroad; our ability to compete against third parties; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; and the other risks set forth in the company’s business plans and presentations. These forward- looking statements speak only as of the date hereof. Metabiomics disclaims any obligation to update these forward-looking statements.

Contact Us

2 + 5 =